Development and validation of nomograms predicting survival in female patients with HER2-positive T1-3N0-1 breast cancer following breast-conserving surgery: a Surveillance, Epidemiology, and End Results database analysis.

ABSTRACT:

Background

Despite advances in human epidermal growth factor receptor 2 (HER2)-targeted therapies, HER2-positive early-stage breast cancer (BC) exhibits substantial outcome heterogeneity after breast-conserving surgery (BCS), complicating personalized chemotherapy sequencing. Robust tools integrating clinicopathological variables and treatment response are urgently needed to optimize survival while minimizing overtreatment. This study aimed to develop and validate a novel prognostic tool for this specific patient population.

Methods

Using Surveillance, Epidemiology, and End Results (SEER) data [2010-2016; HER2-positive T1-3N0-1 BC patients (n=13,875) treated with BCS and radiotherapy], we developed and validated nomograms predicting overall and cancer-specific survival (CSS)

SUBMITTER: Zhu S 

PROVIDER: S-EPMC12685774 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature